#Germany #Frankfurt #Zentiva #APONTIS PHARMA #Pharma Acquisition

Zentiva Completes Public Buyout of APONTIS PHARMA AG

Zentiva AG, an exclusive subsidiary of Zentiva Pharma GmbH headquartered in Frankfurt am Main, recently announced the successful completion of its voluntary public buyout offer for APONTIS PHARMA AG. This acquisition reinforces Zentiva's foothold within the pharmaceutical industry, as it now holds approximately 83.57% of the capital and about 85.27% of the voting rights of APONTIS PHARMA.

Spanning from November 27, 2024, to December 10, 2024, the offering has culminated in a significant partnership poised to generate shared growth and innovation in the healthcare sector. The finalization of this public offer was contingent upon meeting specific conditions outlined in the offer document, all of which have either been satisfied or waived in advance by Zentiva.

The Acquisition's Strategic Impact

This acquisition is not just a routine financial maneuver; it stands as a strategic initiative designed to enhance both companies' capabilities in delivering high-quality, affordable medications to a wider European audience. Following regulatory compliance, the stock market trading of APONTIS PHARMA's shares on the Freiverkehr will cease immediately after the buyout agreement's completion, negating the need for a separate delisting offer.

As part of the investment agreement, the board of APONTIS PHARMA committed to complying with its fiduciary duties while facilitating a smooth transition post-acquisition. Shareholders of APONTIS PHARMA who are considering selling their shares can still reach out to Zentiva, as they are still accepting expressions of interest.

Background on Zentiva

Established as a pan-European platform, Zentiva has dedicated its efforts to the development, production, and distribution of high-quality medications accessible to over 100 million people throughout Europe. The company operates four exclusive production plants and maintains an extensive network of partnerships to ensure an uninterrupted supply chain. This robust operational backbone supports their ongoing commitment to tackle critical health challenges such as cardiovascular diseases, diabetes, oncology, and respiratory disorders, with plans to expand its offerings in self-medication solutions.

With an illustrious workforce of approximately 5,000 employees, Zentiva prides itself on fostering a work environment that promotes inclusivity, professional growth, and a shared commitment to enhancing public health.

Profile of APONTIS PHARMA

APONTIS PHARMA distinguishes itself as a premier pharmaceutical enterprise specializing in single-pill combinations within Germany. By merging two to three generic active ingredients into a single daily dosage, APONTIS PHARMA significantly increases adherence to treatment protocols, thereby enhancing patient prognoses and quality of life while also reducing healthcare costs and complications.

Founded in 2013, APONTIS PHARMA has dedicated itself to the research, promotion, and distribution of unique pill combinations, particularly targeting cardiovascular conditions such as hypertension and hyperlipidemia. Their innovative approach aligns with the best practices outlined in various international therapeutic guidelines.

Final Insights

Overall, the collaboration between Zentiva and APONTIS PHARMA is expected to drive further advancements in pharmaceutical development and broaden their patient care capabilities across Europe. Investors and stakeholders alike are encouraged to monitor this transformative acquisition as it unfolds, with further details available on Zentiva's official offer website.

Important Notice

This publication does not constitute an offer for purchase or a solicitation to sell shares of APONTIS PHARMA or any other securities. It solely pertains to the completion of the voluntary public offer process as defined within the modified offer document. Interested investors should review all relevant documents to understand any implications correctly.

For more information about Zentiva and its operations, please visit www.zentiva.com or www.zentiva.de.